Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol.
Mallard J, Hucteau E, Schott R, Petit T, Demarchi M, Belletier C, Ben Abdelghani M, Carinato H, Chiappa P, Fischbach C, Kalish-Weindling M, Bousinière A, Dufour S, Favret F, Pivot X, Hureau TJ, Pagano AF. Mallard J, et al. Among authors: fischbach c. Front Oncol. 2020 Aug 7;10:1304. doi: 10.3389/fonc.2020.01304. eCollection 2020. Front Oncol. 2020. PMID: 32903594 Free PMC article.
Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.
Carinato H, Burgy M, Ferry R, Fischbach C, Kalish M, Guihard S, Brahimi Y, Flesch H, Bronner G, Schultz P, Frasie V, Thiéry A, Demarchi M, Petit T, Jung AC, Wagner P, Coliat P, Borel C. Carinato H, et al. Among authors: fischbach c. Front Oncol. 2021 Oct 27;11:714551. doi: 10.3389/fonc.2021.714551. eCollection 2021. Front Oncol. 2021. PMID: 34778031 Free PMC article.
Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.
Martin S, Pflumio C, Trensz P, Schaff-Wendling F, Weindling MK, Fischbach C, Pierard L, Limacher JM, Nader R, Velten M, Petit T. Martin S, et al. Among authors: fischbach c. Clin Breast Cancer. 2023 Jan;23(1):32-37. doi: 10.1016/j.clbc.2022.10.006. Epub 2022 Oct 13. Clin Breast Cancer. 2023. PMID: 36414498 Free PMC article.
A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.
Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, Fischbach C, Kalish M, Kurtz JE, Pierard L, Demarchi M, Karouby D, Coliat P, Pivot X, Petit T, Cox DG, Goepp L, Bender L, Trensz P. Bischoff H, et al. Among authors: fischbach c. Breast Cancer Res Treat. 2023 Feb;198(1):23-29. doi: 10.1007/s10549-022-06844-5. Epub 2022 Dec 23. Breast Cancer Res Treat. 2023. PMID: 36562910
Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review.
Moinard-Butot F, Nannini S, Fischbach C, Abdallahoui S, Demarchi M, Petit T, Bender L, Schott R. Moinard-Butot F, et al. Among authors: fischbach c. Cancers (Basel). 2023 Oct 11;15(20):4940. doi: 10.3390/cancers15204940. Cancers (Basel). 2023. PMID: 37894307 Free PMC article. Review.
121 results